EHNAC Announces New Accreditation Program for Cloud-Enabled Service Providers
Feb 10, 2016 13:30 pm UTC| Business
FARMINGTON, Conn., Feb. 10, 2016 -- The Electronic Healthcare Network Accreditation Commission (EHNAC), a non-profit, federally recognized standards development organization and accrediting body for organizations that...
Geology and Finance Industry Veteran Joins Rostock Ventures Corp Board of Directors
Feb 10, 2016 13:30 pm UTC| Business
HENDERSON, Nev., Feb. 10, 2016 -- Rostock Ventures Corp. (OTCBB:ROSV) (the "Company") is pleased to announce that Eric Allison has joined the Company's Board of Directors. Mr. Allison has over 35 years of experience in...
3i-Infotech Executes One of Its Fastest Insurance Projects at Mitsui Sumitomo Insurance Company
Feb 10, 2016 13:10 pm UTC| Business
MUMBAI, India, Feb. 10, 2016 -- Mitsui Sumitomo Insurance Company (MSI) - Dubai, part of the largest conglomerate in the world, has selected 3i-Infotech's flagship Premia General Insurance product. Premia 11 is the...
Feb 10, 2016 13:05 pm UTC| Business
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin B) and MAT2501 (Encochleated Amikacin) - BEDMINSTER, N.J., Feb. 10, 2016 -- Matinas BioPharma...
Feb 10, 2016 13:00 pm UTC| Business
Once granted, the new U.S. patent covering methods of use forRHB-104 is expected to be valid through 2029RHB-104 is undergoing a first Phase III study for the treatment of Crohn’s disease in the U.S. and additional...
MYR Group Announces Results of Capital Allocation Review
Feb 10, 2016 13:00 pm UTC| Business
Board Approves $75 Million Increase to Share Repurchase Program and Implementation of New Financing Strategies to Support a Significant Portion of Its Future Equipment Needs Company Provides Update on Engine Capital,...
Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
Feb 10, 2016 13:00 pm UTC| Business
BURNABY, British Columbia, Feb. 10, 2016 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing patients in a Phase 2 clinical trial of...